Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Panitumumab + mFOLFOX6 ups OS in 1L left-sided RAS wild-type mCRC in Japanese trial
Panitumumab plus modified FOLFOX6 (mFOLFOX6; fluorouracil, leucovorin, and oxaliplatin) as first-line therapy significantly improves overall survival (OS) vs bevacizumab plus mFOLFOX6 in patients with left-sided RAS wild-type (wt) metastatic colorectal cancer (mCRC), results of the Japanese PARADIGM trial have shown.
Upadacitinib works in select ankylosing spondylitis patients
The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.
Anaemia a major indication for obstetric red cell transfusion in multiethnic population
Red cell transfusion at a high-volume tertiary hospital in Singapore has an incidence of 3.2 percent in a multiethnic obstetric population, according to a study. Anaemia during pregnancy is the most common reason for transfusion administration.
Keto or Mediterranean diet for diabetes: Do we have a clear winner?
The ketogenic (keto) diet appears as good as the Mediterranean diet in reducing blood sugar in individuals with prediabetes, or type 2 diabetes (T2D), according to a small, randomized, crossover trial.